Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
12 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Vor Biopharma Inc.’s names, not what it holds today.
Patents granted
12
12 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 2 in 2024 and 2 in 2023
Applications published
42
6 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology9
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Vor Biopharma Inc. its own name
US, as the owner printed on each patent. 6 more under the same name are not counted (printed in GB)
33 publishedVOR BIOPHARMA INC. its own name
named as the applicant on its applications, in US
9 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 2, 2025 | 12,403,200 | Methods and compositions for treating autoimmune diseases | Pharmaceuticals | Vor Biopharma Inc. |
| May 6, 2025 | 12,291,576 | Anti-CD45 antibodies and conjugates thereof | Pharmaceuticals | Vor Biopharma Inc. |
| Mar 18, 2025 | 12,251,403 | Genetically engineered hematopoietic stem cells and uses thereof | Biotechnology | Vor Biopharma Inc. |
| Jan 28, 2025 | 12,209,135 | Anti-CD45 antibodies and conjugates thereof | Pharmaceuticals | Vor Biopharma Inc. |
| May 7, 2024 | 11,975,029 | Compositions and methods for inhibition of lineage specific proteins | Biotechnology | Vor Biopharma Inc. |
| Feb 20, 2024 | 11,903,973 | Genetically engineered hematopoietic stem cells and uses thereof | Biotechnology | Vor Biopharma Inc. |
| Feb 7, 2023 | 11,571,445 | Genetically engineered hematopoietic stem cells and uses thereof | Biotechnology | Vor Biopharma Inc. |
| Jan 24, 2023 | 11,559,551 | Genetically engineered hematopoietic stem cells and uses thereof | Biotechnology | Vor Biopharma Inc. |
| Oct 11, 2022 | 11,464,807 | Genetically engineered hematopoietic stem cells and uses thereof | Biotechnology | Vor Biopharma Inc. |
| Jul 19, 2022 | 11,389,485 | Genetically engineered hematopoietic stem cells and uses thereof | Biotechnology | Vor Biopharma Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 30, 2025 | 2025/0333515 | BINDING AGENTS AND METHODS OF USE THEREOF | Biotechnology | VOR BIOPHARMA INC. |
| Sep 25, 2025 | 2025/0295695 | COMPOSITIONS AND METHODS FOR MEDIATING EPITOPE ENGINEERING | Biotechnology | Vor Biopharma Inc. |
| Jun 5, 2025 | 2025/0179531 | COMPOSITIONS AND METHODS FOR HOMOLOGY-DIRECTED REPAIR GENE MODIFICATION | Biotechnology | Vor Biopharma Inc. |
| May 1, 2025 | 2025/0140342 | GENOTYPING CELLS USING SINGLE-CELL DNA SEQUENCING DATA | Computer technology | Vor Biopharma Inc. |
| Apr 17, 2025 | 2025/0122534 | COMPOSITIONS AND METHODS FOR GENE MODIFICATION | Biotechnology | Vor Biopharma Inc. |
| Mar 13, 2025 | 2025/0082755 | CHIMERIC ANTIGEN RECEPTORS FOR TREATMENT OF CANCER | Medical technology | Vor Biopharma Inc. |
| Dec 19, 2024 | 2024/0417755 | FUSION POLYPEPTIDES FOR GENETIC EDITING AND METHODS OF USE THEREOF | Biotechnology | Vor Biopharma Inc. |
| Dec 12, 2024 | 2024/0408234 | COMPOSITIONS AND METHODS FOR MULTIPLEX BASE EDITING IN HEMATOPOIETIC CELLS | Biotechnology | Vor Biopharma Inc. |
| Dec 12, 2024 | 2024/0408168 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS | Pharmaceuticals | VOR BIOPHARMA INC. |
| Nov 21, 2024 | 2024/0384304 | INHIBITOR OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | Biotechnology | Vor Biopharma Inc. |
What it applied for, 2024 to 2025: Biotechnology 16 · Pharmaceuticals 3 · Medical technology 1 · Computer technology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.